The efficacy of pegylated interferon alpha-2a and entecavir in HBeAg-positive children and adolescents with chronic hepatitis B

作者全名："He, Yi; Zhou, Yingzhi; Wang, Huimin; Peng, Xiaorong; Chang, Yunan; Hu, Peng; Ren, Hong; Xu, Hongmei"

作者地址："[He, Yi; Zhou, Yingzhi; Wang, Huimin; Peng, Xiaorong; Chang, Yunan; Xu, Hongmei] Chongqing Med Univ, Dept Infect,Key Lab Child Dev & Disorders, Childrens Hosp,Chongqing Key Lab Child Infect & I, Natl Clin Res Ctr Child Hlth & Disorders,Minist E, 136,Zhongshan Rd, Chongqing 400014, Peoples R China; [Hu, Peng; Ren, Hong] Chongqing Med Univ, Dept Infect Dis, Key Lab Mol Biol Infect Dis, Inst Viral Hepatitis,Affiliated Hosp 2,Minsit Edu, Chongqing, Peoples R China"

通信作者："Xu, HM (通讯作者)，Chongqing Med Univ, Dept Infect,Key Lab Child Dev & Disorders, Childrens Hosp,Chongqing Key Lab Child Infect & I, Natl Clin Res Ctr Child Hlth & Disorders,Minist E, 136,Zhongshan Rd, Chongqing 400014, Peoples R China."

来源：BMC PEDIATRICS

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:000827743000005

JCR分区：Q2

影响因子：2.4

年份：2022

卷号：22

期号：1

开始页：　

结束页：　

文献类型：Article

关键词：Chronic hepatitis B; Paediatrics; Entecavir; Pegylated interferon; Treatment

摘要："Background and objectives Pegylated interferon alpha-2a (peg-IFN alpha-2a) and entecavir (ETV) are both recommended as the first-line antiviral drugs for chronic hepatitis B (CHB) at present. We aimed to compare the efficacy and safety between peg-IFN alpha-2a and ETV initial therapy in children and adolescents with CHB and investigate the potential factors affecting the treatment response during the first 48 weeks. Methods We retrospectively selected 70 treatment-naive children and adolescents with CHB who received peg-IFN alpha-2a(n = 26) or ETV(n = 44) as initial therapy and completed 48-week follow-up for data analysis. Blood samples before treatment were collected from 26 patients of the cohort to assess the cytokine profiles. Results We found that initial peg-IFN therapy results in higher rates of hepatitis B surface antigen (HBsAg) serological response (SR) but lower rates of virological and biochemical response rates compared to ETV at week 48. As for achieving hepatitis B e antigen (HBeAg) SR, peg-IFN was comparable to ETV in the univariate analysis and turned out to be better than ETV after adjustment for important baseline factors. We also found that elevated pre-treatment IL-18 level was significantly associated with HBeAg SR, and remained as the only independent factor of predicting HBeAg SR after adjustment for other important factors. No serious adverse effects of the 2 drugs were reported during the 48-week follow-up. Conclusions comparing to ETV, peg-IFN was superior in achieving HBsAg and HBeAg SR; higher baseline IL-18 levels were independently associated with HBeAg SR in this study of children and adolescents with CHB."

基金机构：National Science and Technology Major Project of China [2017ZX10202203007008]

基金资助正文：This study was supported by the National Science and Technology Major Project of China [2017ZX10202203007008].